Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …

Chronotherapeutics aim at treating illnesses according to the endogenous biologic rhythms,
which moderate xenobiotic metabolism and cellular drug response. The molecular clocks …

Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …

PURPOSE To provide guidance on the clinical management of dyspnea in adult patients
with advanced cancer. METHODS ASCO convened an Expert Panel to review the evidence …

Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and
progression-free survival, and a higher proportion of patients with a confirmed complete or …

Purpose Understanding of prognosis among terminally ill patients impacts medical decision
making. The aims of this study were to explore perceptions of prognosis and goals of …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …

Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Purpose Patient-reported symptoms and health-related quality of life (QoL) benefits were
investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed. Patients and …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …